Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom. Show more
Location: 50 Broadway, London, SW1H 0DB, United Kingdom | Website: https://roivant.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
7.723B
52 Wk Range
$8.73 - $13.05
Previous Close
$11.57
Open
$11.48
Volume
5,079,624
Day Range
$11.28 - $11.52
Enterprise Value
3.374B
Cash
4.887B
Avg Qtr Burn
-209.9M
Insider Ownership
30.31%
Institutional Own.
83.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Atopic dermatitis | Approved Quarterly sales | |
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
Batoclimab Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Brepocitinib Details Dermatomyositis | Phase 3 Data readout | |
Batoclimab Details Myasthenia gravis | Phase 3 Update | |
RVT-3101 Details Ulcerative colitis | Phase 3 Initiation | |
Brepocitinib Details Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis | Phase 3 Initiation | |
Mosliciguat Details Pulmonary hypertension associated with interstitial lung disease | Phase 2 Data readout | |
RVT-3101 Details Crohns disease | Phase 2 Data readout | |
Brepocitinib Details Sarcoidosis | Phase 2 Initiation | |
Namilumab Details Sarcoidosis | Failed Discontinued | |
RVT-2001 Details Myelodysplastic syndrome | Failed Discontinued |